CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,776 | -31.3% | 1,638,858 | 0.0% | 1.53% | -5.0% |
| Q2 2023 | $52,099 | +11.6% | 1,638,858 | -14.4% | 1.62% | -41.8% |
| Q1 2023 | $46,694 | -22.1% | 1,914,466 | +0.8% | 2.78% | -17.0% |
| Q4 2022 | $59,926 | -99.9% | 1,900,000 | -5.0% | 3.34% | +38.7% |
| Q3 2022 | $56,520,000 | +42.5% | 2,000,000 | +33.3% | 2.41% | +13.9% |
| Q2 2022 | $39,660,000 | -24.5% | 1,500,000 | 0.0% | 2.12% | -3.7% |
| Q1 2022 | $52,515,000 | +8.0% | 1,500,000 | 0.0% | 2.20% | +66.6% |
| Q4 2021 | $48,630,000 | -8.4% | 1,500,000 | -16.7% | 1.32% | +11.1% |
| Q3 2021 | $53,100,000 | +3.6% | 1,800,000 | -10.0% | 1.19% | +14.2% |
| Q2 2021 | $51,240,000 | +49.3% | 2,000,000 | -20.0% | 1.04% | +71.6% |
| Q1 2021 | $34,325,000 | -9.3% | 2,500,000 | +9.5% | 0.61% | -25.4% |
| Q4 2020 | $37,837,000 | – | 2,282,100 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |